WO2019201970A1 - Ligand de mertk pour la thérapie adoptive anicancéreuse par lymphocytes t - Google Patents
Ligand de mertk pour la thérapie adoptive anicancéreuse par lymphocytes t Download PDFInfo
- Publication number
- WO2019201970A1 WO2019201970A1 PCT/EP2019/059877 EP2019059877W WO2019201970A1 WO 2019201970 A1 WO2019201970 A1 WO 2019201970A1 EP 2019059877 W EP2019059877 W EP 2019059877W WO 2019201970 A1 WO2019201970 A1 WO 2019201970A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- mertk
- ligand
- amino acids
- lymphocytes
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title claims abstract description 123
- 238000011275 oncology therapy Methods 0.000 title claims description 13
- 101150082854 Mertk gene Proteins 0.000 title abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 147
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 92
- 201000011510 cancer Diseases 0.000 claims abstract description 66
- 238000000034 method Methods 0.000 claims abstract description 29
- 238000011282 treatment Methods 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 102
- 150000001413 amino acids Chemical class 0.000 claims description 87
- 210000004698 lymphocyte Anatomy 0.000 claims description 57
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 44
- 230000014509 gene expression Effects 0.000 claims description 41
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 39
- 229920001184 polypeptide Polymers 0.000 claims description 36
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 31
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 31
- 239000012634 fragment Substances 0.000 claims description 21
- 102000004127 Cytokines Human genes 0.000 claims description 20
- 108090000695 Cytokines Proteins 0.000 claims description 20
- 238000000338 in vitro Methods 0.000 claims description 20
- 230000035755 proliferation Effects 0.000 claims description 20
- 230000011664 signaling Effects 0.000 claims description 20
- 238000012546 transfer Methods 0.000 claims description 14
- 230000004936 stimulating effect Effects 0.000 claims description 13
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 12
- 201000001441 melanoma Diseases 0.000 claims description 12
- 101150022345 GAS6 gene Proteins 0.000 claims description 11
- 230000003213 activating effect Effects 0.000 claims description 8
- 238000011467 adoptive cell therapy Methods 0.000 claims description 7
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 6
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 101001011441 Homo sapiens Interferon regulatory factor 4 Proteins 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 230000000770 proinflammatory effect Effects 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 102100030126 Interferon regulatory factor 4 Human genes 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 102000000802 Galectin 3 Human genes 0.000 claims description 3
- 108010001517 Galectin 3 Proteins 0.000 claims description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 206010073073 Hepatobiliary cancer Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
- 206010024291 Leukaemias acute myeloid Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010028729 Nasal cavity cancer Diseases 0.000 claims description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 208000010505 Nose Neoplasms Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000032383 Soft tissue cancer Diseases 0.000 claims description 2
- 108700012920 TNF Proteins 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000023915 Ureteral Neoplasms Diseases 0.000 claims description 2
- 206010046392 Ureteric cancer Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 2
- 206010065867 alveolar rhabdomyosarcoma Diseases 0.000 claims description 2
- 210000002255 anal canal Anatomy 0.000 claims description 2
- 201000007696 anal canal cancer Diseases 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 210000000959 ear middle Anatomy 0.000 claims description 2
- 208000024519 eye neoplasm Diseases 0.000 claims description 2
- 210000000232 gallbladder Anatomy 0.000 claims description 2
- 201000007487 gallbladder carcinoma Diseases 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000006866 hypopharynx cancer Diseases 0.000 claims description 2
- 210000003228 intrahepatic bile duct Anatomy 0.000 claims description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
- 201000004962 larynx cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000006178 malignant mesothelioma Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000025848 malignant tumor of nasopharynx Diseases 0.000 claims description 2
- 208000026037 malignant tumor of neck Diseases 0.000 claims description 2
- 210000000713 mesentery Anatomy 0.000 claims description 2
- 201000003956 middle ear cancer Diseases 0.000 claims description 2
- 210000000214 mouth Anatomy 0.000 claims description 2
- 210000003928 nasal cavity Anatomy 0.000 claims description 2
- 201000007425 nasal cavity carcinoma Diseases 0.000 claims description 2
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 2
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 2
- 201000008106 ocular cancer Diseases 0.000 claims description 2
- 210000002747 omentum Anatomy 0.000 claims description 2
- 230000002611 ovarian Effects 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 210000004303 peritoneum Anatomy 0.000 claims description 2
- 201000008006 pharynx cancer Diseases 0.000 claims description 2
- 210000004224 pleura Anatomy 0.000 claims description 2
- 201000003437 pleural cancer Diseases 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000002314 small intestine cancer Diseases 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 201000011294 ureter cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 210000000777 hematopoietic system Anatomy 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 238000002659 cell therapy Methods 0.000 abstract 2
- 102100028885 Vitamin K-dependent protein S Human genes 0.000 description 75
- 101000577630 Homo sapiens Vitamin K-dependent protein S Proteins 0.000 description 74
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 73
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 55
- 102100022356 Tyrosine-protein kinase Mer Human genes 0.000 description 40
- 108010018804 c-Mer Tyrosine Kinase Proteins 0.000 description 36
- 108090000623 proteins and genes Proteins 0.000 description 21
- 108091008874 T cell receptors Proteins 0.000 description 16
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 16
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 14
- 230000002147 killing effect Effects 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108020004459 Small interfering RNA Proteins 0.000 description 11
- 230000000638 stimulation Effects 0.000 description 11
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 10
- 108091005729 TAM receptors Proteins 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 238000003197 gene knockdown Methods 0.000 description 10
- 208000021039 metastatic melanoma Diseases 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 7
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- 238000003501 co-culture Methods 0.000 description 7
- 239000012228 culture supernatant Substances 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 6
- 102100040247 Tumor necrosis factor Human genes 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000001574 biopsy Methods 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000012679 serum free medium Substances 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- BMZRVOVNUMQTIN-UHFFFAOYSA-N Carbonyl Cyanide para-Trifluoromethoxyphenylhydrazone Chemical compound FC(F)(F)OC1=CC=C(NN=C(C#N)C#N)C=C1 BMZRVOVNUMQTIN-UHFFFAOYSA-N 0.000 description 5
- 206010057248 Cell death Diseases 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000000284 resting effect Effects 0.000 description 5
- MNULEGDCPYONBU-WMBHJXFZSA-N (1r,4s,5e,5'r,6'r,7e,10s,11r,12s,14r,15s,16s,18r,19s,20r,21e,25s,26r,27s,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trio Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 MNULEGDCPYONBU-WMBHJXFZSA-N 0.000 description 4
- MNULEGDCPYONBU-DJRUDOHVSA-N (1s,4r,5z,5'r,6'r,7e,10s,11r,12s,14r,15s,18r,19r,20s,21e,26r,27s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers O([C@H]1CC[C@H](\C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)C(C)C(=O)[C@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)OC([C@H]2C)C1C)CC)[C@]12CC[C@@H](C)[C@@H](CC(C)O)O1 MNULEGDCPYONBU-DJRUDOHVSA-N 0.000 description 4
- MNULEGDCPYONBU-YNZHUHFTSA-N (4Z,18Z,20Z)-22-ethyl-7,11,14,15-tetrahydroxy-6'-(2-hydroxypropyl)-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione Polymers CC1C(C2C)OC(=O)\C=C/C(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)C\C=C/C=C\C(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-YNZHUHFTSA-N 0.000 description 4
- MNULEGDCPYONBU-VVXVDZGXSA-N (5e,5'r,7e,10s,11r,12s,14s,15r,16r,18r,19s,20r,21e,26r,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers C([C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)OC([C@H]1C)[C@H]2C)\C=C\C=C\C(CC)CCC2OC21CC[C@@H](C)C(C[C@H](C)O)O2 MNULEGDCPYONBU-VVXVDZGXSA-N 0.000 description 4
- MJSHVHLADKXCML-UHFFFAOYSA-N 4-[2-(butylamino)-5-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexan-1-ol Chemical compound C12=NC(NCCCC)=NC=C2C(C=2C=CC(CN3CCN(C)CC3)=CC=2)=CN1C1CCC(O)CC1 MJSHVHLADKXCML-UHFFFAOYSA-N 0.000 description 4
- MNULEGDCPYONBU-UHFFFAOYSA-N 4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers CC1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)CC=CC=CC(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 108010002586 Interleukin-7 Proteins 0.000 description 4
- 102000000704 Interleukin-7 Human genes 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 230000006052 T cell proliferation Effects 0.000 description 4
- 230000002715 bioenergetic effect Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000016396 cytokine production Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000006540 mitochondrial respiration Effects 0.000 description 4
- 229930191479 oligomycin Natural products 0.000 description 4
- MNULEGDCPYONBU-AWJDAWNUSA-N oligomycin A Polymers O([C@H]1CC[C@H](/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]([C@@H]2C)[C@@H]1C)CC)[C@@]12CC[C@H](C)[C@H](C[C@@H](C)O)O1 MNULEGDCPYONBU-AWJDAWNUSA-N 0.000 description 4
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 3
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 3
- 108060001253 CD99 Proteins 0.000 description 3
- 102000024905 CD99 Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102100027085 Dual specificity protein phosphatase 4 Human genes 0.000 description 3
- 241001559542 Hippocampus hippocampus Species 0.000 description 3
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 3
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 3
- 101001057621 Homo sapiens Dual specificity protein phosphatase 4 Proteins 0.000 description 3
- 101001046683 Homo sapiens Integrin alpha-L Proteins 0.000 description 3
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 description 3
- 101000973901 Homo sapiens Tyrosine-protein kinase Mer Proteins 0.000 description 3
- 102100022339 Integrin alpha-L Human genes 0.000 description 3
- 102100039078 Interleukin-4 receptor subunit alpha Human genes 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 101710103890 Tyrosine-protein kinase Mer Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000005754 cellular signaling Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 210000003162 effector t lymphocyte Anatomy 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 230000002414 glycolytic effect Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000017073 interleukin-7 production Effects 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000011201 multiple comparisons test Methods 0.000 description 3
- 230000036284 oxygen consumption Effects 0.000 description 3
- 101150080066 proS1 gene Proteins 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000007306 turnover Effects 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 102000004121 Annexin A5 Human genes 0.000 description 2
- UIFFUZWRFRDZJC-UHFFFAOYSA-N Antimycin A1 Natural products CC1OC(=O)C(CCCCCC)C(OC(=O)CC(C)C)C(C)OC(=O)C1NC(=O)C1=CC=CC(NC=O)=C1O UIFFUZWRFRDZJC-UHFFFAOYSA-N 0.000 description 2
- NQWZLRAORXLWDN-UHFFFAOYSA-N Antimycin-A Natural products CCCCCCC(=O)OC1C(C)OC(=O)C(NC(=O)c2ccc(NC=O)cc2O)C(C)OC(=O)C1CCCC NQWZLRAORXLWDN-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 2
- 108010008978 Chemokine CXCL10 Proteins 0.000 description 2
- 102000006579 Chemokine CXCL10 Human genes 0.000 description 2
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108091077436 Tam family Proteins 0.000 description 2
- 210000005006 adaptive immune system Anatomy 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- UIFFUZWRFRDZJC-SBOOETFBSA-N antimycin A Chemical compound C[C@H]1OC(=O)[C@H](CCCCCC)[C@@H](OC(=O)CC(C)C)[C@H](C)OC(=O)[C@H]1NC(=O)C1=CC=CC(NC=O)=C1O UIFFUZWRFRDZJC-SBOOETFBSA-N 0.000 description 2
- PVEVXUMVNWSNIG-UHFFFAOYSA-N antimycin A3 Natural products CC1OC(=O)C(CCCC)C(OC(=O)CC(C)C)C(C)OC(=O)C1NC(=O)C1=CC=CC(NC=O)=C1O PVEVXUMVNWSNIG-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- SCJNCDSAIRBRIA-DOFZRALJSA-N arachidonyl-2'-chloroethylamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCCl SCJNCDSAIRBRIA-DOFZRALJSA-N 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 230000009274 differential gene expression Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 102000045684 human MERTK Human genes 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000007492 two-way ANOVA Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 description 1
- POVNCJSPYFCWJR-USZUGGBUSA-N (4s)-4-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-[(2s)-2-[[2-[(2s)-2-[[(2s)-1-[[(2s,3r)-1-[[(1s)-1-carboxy-2-methylpropyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1- Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O)C1=CC=C(O)C=C1 POVNCJSPYFCWJR-USZUGGBUSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100084421 Caenorhabditis elegans pros-1 gene Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241001466804 Carnivora Species 0.000 description 1
- 108010029240 Cell-Tak Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 240000008168 Ficus benjamina Species 0.000 description 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000824104 Homo sapiens High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101000699762 Homo sapiens RNA 3'-terminal phosphate cyclase Proteins 0.000 description 1
- 101000653540 Homo sapiens Transcription factor 7 Proteins 0.000 description 1
- 101000606129 Homo sapiens Tyrosine-protein kinase receptor TYRO3 Proteins 0.000 description 1
- 101000759926 Homo sapiens Ubiquitin carboxyl-terminal hydrolase isozyme L1 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108010010995 MART-1 Antigen Proteins 0.000 description 1
- 102000016200 MART-1 Antigen Human genes 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 102100029143 RNA 3'-terminal phosphate cyclase Human genes 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 206010038111 Recurrent cancer Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241001493546 Suina Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102000003715 TNF receptor-associated factor 4 Human genes 0.000 description 1
- 108090000008 TNF receptor-associated factor 4 Proteins 0.000 description 1
- 102100030627 Transcription factor 7 Human genes 0.000 description 1
- 101150098329 Tyro3 gene Proteins 0.000 description 1
- 102100039127 Tyrosine-protein kinase receptor TYRO3 Human genes 0.000 description 1
- 229940127174 UCHT1 Drugs 0.000 description 1
- 102100025038 Ubiquitin carboxyl-terminal hydrolase isozyme L1 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- -1 e.g. Proteins 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000006539 extracellular acidification Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229940126546 immune checkpoint molecule Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 108010028930 invariant chain Proteins 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000011499 palliative surgery Methods 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- CCEKAJIANROZEO-UHFFFAOYSA-N sulfluramid Chemical group CCNS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CCEKAJIANROZEO-UHFFFAOYSA-N 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464462—Kinases, e.g. Raf or Src
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1114—T cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
Definitions
- the present invention relates to a Mer Tyrosine Kinase (MerTK) ligand for use in adoptive T cell transfer cancer therapy in an individual.
- MerTK Mer Tyrosine Kinase
- Cancer immunotherapy may be divided into three major categories: non-specific stimulation of the immune system, active immunization using cancer vaccines, and adoptive cell transfer immunotherapy.
- Adoptive cell transfer is based on transfer of immune cells with anti-tumor activity into cancer patients.
- T cells are generally divided into CD4 and CD8 T cells.
- CD4 T cells are functionally plastic and may possess helper function for CD8 T cells, but may also differentiate into regulatory T cells which suppress CD8 T cell responses.
- CD8 T cells are less plastic and this cell type has as its main function to kill cells - be it infected cells (e.g., with virus) or cancer cells.
- T cells used for ACT can be derived from tumor tissue (tumor infiltrating lymphocytes or TILs). TILs comprise relatively high frequencies of tumor specific T cells which can be expanded in vitro and transferred back to the patient in what is called“TIL based ACT” therapy. Blood T cells can also be used for harvest of cells. For treatment of cancer, tumor specific T cells are, however, scarce in blood, but T cells harvested from blood may be genetically engineered to express T cell receptors (TCRs) that recognize human leukocyte antigen (HLA)/peptide complexes expressed by cancer cells, or chimeric antigen receptors (CARs) which equip the cells with antibody recognition capacity, i.e., unleash the killing capacity based on expression of a molecule expressed on the cell surface.
- TCRs T cell receptors
- HLA human leukocyte antigen
- CARs chimeric antigen receptors
- CD4 T cells may play a role in ACT.
- ACT a mutated antigen
- CD8 T cells are the main cell types associated with clinical response in ACT therapy.
- TIL based ACT in melanoma CD8 frequency in administered TIL cultures is associated with clinical response (Andersen et al. 2016, Rosenberg et al. 2011 ).
- CD8 act as a co-stimulatory molecule to HLA class I which is expressed by all nucleated cells including cancer cells
- CD4 is a co-receptor for HLA class II molecules which is only expressed by antigen presenting cells.
- gd T cells expressing a gd T cell receptor
- invariant chain T cells which express a TCR with limited heterogeneity
- NK T cells - expressing a T cell receptor along with more NK cell recognition and killing features - could potentially be exploited in ACT.
- ACT based on the killing capacity of CD8 T cells is by far the most mature and clinically validated.
- Mer Tyrosine Kinase is a member of the TAM family of receptor kinases which consists of Tyro3, Axl, and Mer. Best described ligands for TAM are are growth arrest- specific protein (Gas6) and Protein S (Prosl ). Gas6 is a ligand for all three TAMs whereas Prosl is a ligand for Tyro and MerTK only.
- Cabezon et al. 2015 disclose expression of MerTK and Prosl in activated CD4 T cells and that addition of Prosl to activated CD4 T cell cultures induces proliferation and cytokine production.
- the present inventors have surprisingly found that CD8+ T lymphocytes express MerTK and Prosl and that stimulation of these cells with a MerTK ligand, such as Prosl , leads to increased proliferation and pro-inflammatory cytokine release.
- a MerTK ligand such as Prosl
- the present inventors propose an improved method for adoptive T cell transfer cancer therapy wherein T cells are stimulated by a MerTK ligand thereby increasing their tumor reactivity.
- the present disclosure relates to a Mer Tyrosine Kinase (MerTK) ligand for use in a method of adoptive cell transfer cancer therapy in an individual.
- the method may be performed by the following steps:
- Mer Tyrosine Kinase also referred to as c-mer, Mer, MER, Proto-oncogene c-Mer, Receptor Tyrosine Kinase MerTK, Tyrosine-protein Kinase Mer, STK Kinase, RP38, or MGC133349
- MME133349 is a member of the TAM family of receptor tyrosine kinases, which also include AXL and TYR03 kinases.
- MerTK transduces signals from the extracellular space via activation by binding of ligands, most notably Gas-6, a soluble protein and Prosl .
- ligands most notably Gas-6, a soluble protein and Prosl .
- Three other TAM ligands have recently been described: Galectin-3, Tubby, and Tulp-1.
- CD8+ T lymphocytes kill target cells expressing the cognate antigenic peptide target.
- the term“CD8 T cells” or“CD8+ T lymphocytes” as used interchangeably herein refers to conventional CD8 positive Hla class I restricted T lymphocytes of the adaptive immune system. Memory T cells are a subset of T cells that have previously encountered and responded to their cognate antigen. These cells are long lived.
- TCM refers to T central memory cells.
- TILs Tumor infiltrating lymphocytes
- TILs are white blood cells that have left the bloodstream and migrated into a tumor.
- ACT Adoptive cell therapy, abbreviated ACT is herein used interchangeably with the term adoptive cell transfer.
- ACT involves the transfer of immune cells with antitumor activity into cancer patients.
- ACT is a treatment approach that usually involves the
- Autologous a situation in which the donor and recipient of e.g. lymphocytes are the same person.
- Heterologous a situation in which the donor and recipient of e.g. lymphocytes are not the same person.
- Cytokines are small, secreted polypeptides from higher eukaryotes which are responsible for intercellular signal transduction and which affect the proliferation, division and functions of other cells. They are potent, pleiotropic polypeptides that, e.g. via corresponding receptors, act as local or systemic intercellular regulatory factors, and therefore play crucial roles in many biologic processes, such as immunity, inflammation, and hematopoiesis. Cytokines are produced by diverse cell types including fibroblasts, endothelial cells, epithelial cells, macrophages/monocytes, and lymphocytes.)
- Interleukins are a group of cytokines important for the function of the immune system.
- Pro-inflammatory refers to an agent capable of promoting inflammation.
- Pro-inflammatory cytokines include TNF-a, IFN-g and lnterleukin-2 (IL-2). Description of Drawings
- FIG. 1 MerTK receptor and ligand PROS1 are expressed by TCR-activated human CD8+ T cells.
- Human CD8+ T cells were negatively isolated from peripheral blood mononuclear cells (PBMCs) and activated with aCD3/CD28 beads.
- A Representative histogram of
- F Representative histogram of (E).
- G MerTK protein expression (top) on day 3 of activation of PBMCs or CD8+ T cells, as analysed by western blot (representative of at least 3 independent experiments) b-actin (bottom) served as a loading control. Data are plotted as mean ⁇ SEM. *p ⁇ 0.05, **p ⁇ 0.01 , ***p ⁇ 0.001.
- PROS1 positively regulates CD8+ T cell proliferation.
- (B) Relative proliferation, with aCD3/CD28 activated CD8+ T cells set as 100, of activated CD8+ T cells cultured for 3 days in the presence or absence of 50 nM PROS1 (n 4).
- (C) IFN-g and (D) TNF-a production in culture supernatants (n 3).
- F Representative histogram of (E). Data are plotted as mean ⁇ SEM. *p ⁇ 0.05, **p ⁇ 0.01 , ***p ⁇ 0.001.
- PROS1 impacts on human melanoma TIL expansion.
- TILs from 4 metastatic melanoma patients were isolated, cultured and expanded according to the clinical Rapid Expansion Protocol (REP, with human serum-containing medium, 6000U/ml IL-2, and feeder cells) in the presence or absence of 50 nM PROS1 or aPROS1 mAb.
- the figure represents a schematic representation of domains in Gas6 and Prosl .
- the domains predicted to be involved in TAM binding are the laminin G-like domains 1 and 2.
- CM central-memory
- EM effector-memory
- TEMRA terminally differentiated EM cells. Data are plotted as mean ⁇ SEM and statistical significance was determined with Student’s t tests or two- way ANOVA with Bonferroni’s multiple comparisons tests. *p ⁇ 0.05, **p ⁇ 0.01 ,
- MERTK is expressed by naturally occurring activated peripheral CD8+ T cells.
- CD137+ T cells (CD137+) T cells.
- C Representative histogram of MERTK on CD137- and CD137+ CD8+ T cells.
- MERTK acts as a co-stimulatory molecule on CD8+ T cells.
- siRNA-mediated knockdown (compared to control) of MERTK on three-day CD3/CD28-stimulated CD8+ T cells, followed for 24, 48 and 72h after siRNA knockdown as analyzed by MERTK protein expression via westernblot (representative of at least 3 independent experiments) b-actin (bottom) served as a loading control.
- C) Cytokine concentrations (IFN-g, IL-2, IL-7, IL-15) in supernatants of MERTK-knockdown and control CD8+ T cells re-stimulated overnight with aCD3/CD28, 48 hours after siRNA knockdown (n 4).
- D) Human CD8+ T cells were cultured in serum-free medium, stained with a proliferation dye and activated for three days with aCD3/CD28 in the presence or absence of 250 nM MERTK-inhibitor UNC2025. Proliferation was measured by flow cytometry and relative proliferation was calculated compared to control (n 3).
- TILs Tumor infiltrating lymphocytes
- CM central-memory
- EM effector-memory
- TEMRA terminally differentiated EM cells.
- C TAM receptor protein expression status of tumor cells from 3 metastatic melanoma patients.
- Actin was used a loading control.
- D Real- time in vitro cytolysis of autologous cancer cells from metastatic melanoma patient 3 after addition of antigen-selected autologous TILs (1 :10 or 1 :20 targeheffector ratio).
- E % Cytolysis 48 hours post TIL addition. Data are plotted as mean ⁇ SEM and statistical significance was determined with two-way AN OVA with Bonferroni’s multiple comparisons tests (A). *p ⁇ 0.05, **p ⁇ 0.01 , ***p ⁇ 0.001.
- Figure 10 Blocking PROS1 -MERTK axis decreases mitochondrial respiration in CD8+ T cells.
- Basal respiration was determined as initial resting consumption of oxygen.
- B ATP turnover was measured as decrease of oxygen consumption after addition of oligomycin.
- C Reserve respiratory capacity was measured as percentage of basal respiration, after addition of Carbonyl cyanide-4- (trifluoromethoxy)phenylhydrazone (FCCP).
- D Glycolytic capacity was measured after addition of oligomycin.
- E Raw levels of oxygen consumption. Cells were treated with either oligomycin or FCCP at stage A and antimycin A at stage B.
- F Whole-cells levels of ATP normalized to control. Data are plotted as mean ⁇ SEM and statistical significance was determined with Student’s t tests (A,B,C,D,F). *p ⁇ 0.05, **p ⁇ 0.01 , ***p ⁇ 0.001.
- Blocking PROS1 -MERTK axis decreases mitochondrial respiration in CD8+ T cells.
- Nanostring-measured IRF4 mRNA expression in three-day activated CD8+ T cells analyzed as in Figure 8.
- PROS1 impacts on anti-tumor tumor-infiltrating lymphocytes.
- A Representative dot plots of PROS1 and MERTK co-staining on CD8+ T cells, activated for 3 days with aCD3/CD28 in the presence or absence of 5 mg/ml unconjugated Annexin V.
- SEQ ID NO: 1 is the full length Prosl polypeptide having the following sequence:
- SEQ ID NO: 2 is a fragment of Prosl and comprises an alternative predicted sequence of the LG-like binding domain 1 known to be involved in MerTK binding and
- SEQ ID NO: 3 is a fragment of Prosl and comprises an alternative predicted sequence of the LG-like binding domain 2 known to be involved in MerTK binding and
- SEQ ID NO: 4 is fragment of Prosl and comprises a predicted sequence of the LG-like binding domain 1 as shown in fig 4 and corresponds to amino acids 299-475 of SEQ ID NO: 1 :
- SEQ ID NO: 5 is a fragment of Prosl and comprises a predicted sequence of the LG- like binding domain 2 as shown in fig. 4 and corresponds to amino acids 484-666 of SEQ ID NO: 1 :
- SEQ ID NO: 6 is a fragment of Prosl and comprises a predicted sequence comprising the LG-like binding domains 1 and 2 as shown in fig. 4 and corresponds to amino acids 299-666 of SEQ ID NO: 1 :
- SEQ ID NO: 7 is a fragment of Prosl and comprises a predicted sequence comprising the LG-like binding domains 1 and 2 and corresponds to amino acids 329-647 of SEQ ID NO: 1 :
- SEQ ID NO: 8 is fragment of Prosl and comprises amino acids predicted to be involved in binding to MerTK and corresponds to amino acids 42-666 of SEQ ID NO:1 :
- the present disclosure provides a method for improving the clinical efficacy of ACT by using T lymphocytes which have been stimulated with a MerTK ligand.
- the present disclosure relates to a Mer Tyrosine Kinase (MerTK) ligand for use in a method of adoptive cell transfer cancer therapy in an individual comprising the consecutive steps of
- the present disclosure relates to in vitro method of stimulating CD8+ T lymphocyte proliferation and/or cytokine release comprising the steps of
- said method further comprises administering a therapeutically effective amount of a MerTK ligand, such as Prosl to said individual.
- the MerTK ligand maybe be administered once a week, for example twice a week, such as three times a week, for example four times a week, such as five times a week, for example six times a week, such as daily or for example monthly.
- the MerTK ligand such as Prosl
- the MerTK ligand can e.g. be administered throughout treatment of said individual, i.e. until the tumour has regressed/decreased and/or until amelioration of symptoms and/or until said individual is cured.
- the MerTK ligand may be administered prior to, simultaneously with or after the T lymphocytes to said individual.
- T lymphocytes The stimulation of T lymphocytes with the MerTK ligand is believed to stimulate tumor cell immunogenicity, thereby augmenting tumor reactivity of T lymphocytes.
- An increase in T lymphocyte reactivity will result in enhanced efficacy of adoptive cell therapy (ACT).
- ACT adoptive cell therapy
- ACT involves the transfer of lymphocytes with anti-tumor activity into cancer patients.
- ACT is a treatment approach that usually involves the identification, in vitro, of lymphocytes with anti-tumor activity, the in vitro expansion of these cells to large numbers and their infusion into the cancer-bearing host.
- Lymphocytes used for adoptive transfer can either be derived from the stroma of resected tumors (tumor infiltrating lymphocytes or TILs), or from blood: genetically engineered to express anti- tumor T cell receptors (TCRs) or chimeric antigen receptors (CARs) as described previously by Rosenberg (Rosenberg et al., 2011 ); enriched with mixed lymphocyte tumor cell cultures (MLTCs) as described by Mazzarella (Mazzarella et al., 2012) or cloned using autologous antigen presenting cells and tumor derived peptides as described by Yee (Yee et al., 2002).
- TCRs tumor T cell receptors
- CARs chimeric antigen receptors
- the lymphocytes used for infusion can be isolated from a donor, or from the cancer-bearing host itself.
- ACT in which the lymphocytes originate from the cancer-bearing host to be infused is termed autologous ACT.
- ACT in which the lymphocytes originate from a donor to be infused is termed heterologous ACT.
- ACT may be performed by (i) obtaining lymphocytes from an individual, (ii) culturing said lymphocytes with a MerTK ligand, and (iii) administering the expanded lymphocytes to the individual.
- the lymphocytes are usually expanded prior to administration to the individual.
- the lymphocytes are tumor-derived, i.e. they are TILs, and are isolated from the individual to be treated, i.e. autologous transfer.
- the cancer therapy comprises heterologous adoptive cell therapy of T lymphocytes.
- the MerTK ligand as described herein is capable of activating MerTK signalling and of stimulating proliferation and/or cytokine release of T cells.
- the ligand that specifically binds to MerTK is selected from the group of Prosl , Gas6, Galectin-3, Tubby and Tulp-1 , or active fragments, variants or variants of fragments thereof.
- the MerTK ligand is a Prosl polypeptide, which may be full length Prosl , an active variant of Prosl , a fragment of Pros 1 or a variant of a fragment of Prosl .
- the MerTK ligand is a Prosl polypeptide in the form of a fragment or variant of full length Prosl (SEQ ID NO: 1 ) comprising the amino acid residues which are involved in binding of Prosl to MerTK.
- the MerTK ligand is a Prosl polypeptide comprising an amino acid sequence according to SEQ ID NO: 2 and/or SEQ ID NO: 3.
- SEQ ID NO: 2 and SEQ ID NO: 3 are predicted sequences of LG-like domains 1 and 2 and have been predicted to be involved in Prosl binding to MerTK.
- the MerTK ligand is a Prosl polypeptide comprising an amino acid sequence according to SEQ ID NO: 4 and/or SEQ ID NO: 5.
- SEQ ID NO: 4 and SEQ ID NO: 5 are predicted sequences of LG-like domains 1 and 2 (as shown in fig. 4) and have been predicted to be involved in Prosl binding to MerTK.
- the MerTK ligand is a Prosl polypeptide comprising a variant of SEQ ID NO: 2 and/or SEQ ID NO: 3 having at least 80% sequence identity to said sequences, such as least 85% sequence identity to said sequences, for example at least 90% sequence identity to said sequences, such as at least 95% sequence identity to said sequences, for example at least 97% sequence identity to said sequences.
- sequence identity is at least 90%.
- the MerTK ligand is a Prosl polypeptide comprising a variant of SEQ ID NO: 4 and/or SEQ ID NO: 5 having at least 80% sequence identity to said sequences, such as least 85% sequence identity to said sequences, for example at least 90% sequence identity to said sequences, such as at least 95% sequence identity to said sequences, for example at least 97% sequence identity to said sequences.
- sequence identity is at least 90%.
- the MerTK ligand is a Prosl polypeptide comprising SEQ ID NO: 6 or a variant thereof having at least 80% sequence identity to said sequence, such as least 85% sequence identity to said sequence, for example at least 90% sequence identity to said sequence, such as at least 95% sequence identity to said sequence, for example at least 97% sequence identity to said sequence.
- sequence identity is at least 90%.
- the MerTK ligand is a Prosl polypeptide comprising SEQ ID NO: 7 or a variant thereof having at least 80% sequence identity to said sequence, such as least 85% sequence identity to said sequence, for example at least 90% sequence identity to said sequence, such as at least 95% sequence identity to said sequence, for example at least 97% sequence identity to said sequence.
- sequence identity is at least 90%.
- the MerTK ligand is a Prosl polypeptide comprising an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 1 , such as least 85% sequence identity to SEQ ID NO: 1 , for example at least 90% sequence identity to SEQ ID NO: 1 , such as at least 95% sequence identity to SEQ ID NO: 1 , for example at least 97% sequence identity to SEQ ID NO: 1 , or a fragment thereof comprising at least 150 amino acids, such as at least 200 amino acids, for example at least 250 amino acids, such as at least 300 amino acids, for example at least 350 amino acids, such as at least 400 amino acids, for example at least 450 amino acids, such as at least 500 amino acids, for example at least 550 amino acids, such as at least 600 amino acids, for example at least 650 amino acids.
- the MerTK ligand is a Prosl polypeptide comprising or consisting of SEQ ID NO: 8 or a fragment or variant thereof.
- SEQ ID NO: 1 comprises amino acid residues which are involved in binding of Prosl to MerTK.
- the Prosl polypeptide comprises SEQ ID NO: 8 or a variant thereof having at least 80% sequence identity to said sequence, such as least 85% sequence identity to said sequence, for example at least 90% sequence identity to said sequence, such as at least 95% sequence identity to said sequence, for example at least 97% sequence identity to said sequence.
- the sequence identity is at least 90%.
- the MerTK ligand is a polypeptide, such as a Prosl polypeptide comprising less than 700 amino acids, such as less than 650 amino acids, for example less than 600 amino acids, such as less than 550 amino acids, for example less than 500 amino acids, such as less than 450 amino acids, for example less than 400 amino acids, such as less than 350 amino acids, for example less than 300 amino acids, such as less than 250 amino acids, for example less than 200 amino acids, such as less than 150 amino acids.
- a polypeptide such as a Prosl polypeptide comprising less than 700 amino acids, such as less than 650 amino acids, for example less than 600 amino acids, such as less than 550 amino acids, for example less than 500 amino acids, such as less than 450 amino acids, for example less than 400 amino acids, such as less than 350 amino acids, for example less than 300 amino acids, such as less than 250 amino acids, for example less than 200 amino acids, such as less than 150 amino acids.
- the MerTK ligand is a polypeptide, such as a Prosl polypeptide, comprising less than 500 amino acids.
- the MerTK ligand is a polypeptide, such as a Prosl polypeptide, comprising less than 300 amino acids.
- the MerTK ligand is a polypeptide, such as a Prosl polypeptide, comprising less than 150 amino acids.
- the MerTK ligand is a polypeptide, such as a Prosl polypeptide comprising at least 100 amino acids, such as at least 150 amino acids, for example at least 200 amino acids, such as at least 250 amino acids, for example at least 300 amino acids, such as at least 350 amino acids, for example at least 400 amino acids, such as at least 450 amino acids, for example at least 500 amino acids, such as at least 550 amino acids, for example at least 600 amino acids, such as at least 650 amino acids.
- the MerTK ligand is a polypeptide, such as a Pros1 polypeptide comprising at least 100 amino acids.
- the MerTK ligand is a polypeptide, such as a Pros1 polypeptide comprising at least 300 amino acids.
- the MerTK ligand is a polypeptide, such as a Pros1 polypeptide comprising at least 500 amino acids.
- the MerTK ligand is a Gas6 polypeptide, which may be full length Gas6, an active variant of Gas6, a fragment of Gas6 or a variant of a fragment of Gas6.
- the MerTK ligand is provided in an amount capable of activating MerTK.
- the MerTK ligand is provided in the amount between about 10nM to about 1000nM, for example about 10nM to about 900 nM, such as about 10nM to about 800nM, for example about 10nM to about 700nM, such as about 10nM to about 600nM, for example about 10nM to about 500nM, such as about 10nM to about 400nM, for example about 10nM to about 300nM, such as about 10nM to about 200nM, for example about 10nM to about 100nM, for example about 50nM.
- the MerTK ligand is provided in the amount between about 10nM to about 100nM, for example about 10nM to about 90nM, such as about 10nM to about 80nM, for example about 10nM to about 70nM, such as about 10nM to about 60nM, for example about 10nM to about 50nM, such as about 10nM to about 40nM, for example about 10nM to about 30nM, such as about 10nM to about 20nM.
- the MerTK ligand promotes the proliferation and cytokine production by CD8+ T cells.
- the ability of CD8 T cells to proliferate and produce cytokines plays an important role in the capacity of such T cells to control tumor progression.
- the MerTK ligand promotes the secretion of pro-inflammatory cytokines by CD8+ T cells. In yet another embodiment, the MerTK ligand promotes the secretion of interleukins by CD8+ T cells. In yet another embodiment, the MerTK ligand promotes the secretion of interferons such as IFNy by CD8+ T cells. In yet another embodiment, the MerTK ligand promotes the secretion of TNFa by CD8+ T cells. In yet another embodiment, the MerTK ligand promotes the secretion of IL-2 by CD8+ T cells.
- the MerTK ligand upregulates IRF4 expression.
- the term upregulates used herein is to be understood as an increase in the quantity of a cellular component, such as RNA or protein in response to the said MerTK ligand stimulation.
- an antibody capable of stimulating MerTK signalling for use as a MerTK ligand.
- Antibodies that specifically bind to human Mer Tyrosine Kinase (MerTK) capable of stimulating MerTK signalling are described in, e.g., WO2016106221 , which is incorporated herein by reference in its entirety.
- TILs may be obtained from the stroma of resected tumors. Tumor samples are obtained from patients and a single cell suspension is obtained. The single cell suspension can be obtained in any suitable manner, e.g., mechanically (disaggregating the tumor using, e.g., a gentleMACS (TM) Dissociator, Miltenyi Biotec, Auburn, Calif.) or enzymatically (e.g., collagenase or DNase). Alternatively, T cells may be grown from tumor pieces by IL-2 and MerTK ligand with or without activating CD3 antibody
- the population of T lymphocytes Prior to administration of the MerTK ligand, the population of T lymphocytes is stimulated by an agent capable of stimulating MerTK expression.
- the agent is selected from the group consisting of activating CD3 antibody, activating CD28 antibody, IL-2 and combinations thereof.
- the population of T lymphocytes comprises or consists essentially of CD8+ T lymphocytes.
- the CD8+ T cells comprise effector T lymphocytes expressing CD8.
- the T lymphocytes are usually conventional CD8 positive Hla class I restricted T cells of the adaptive immune system, expressing variant ab T cell receptors.
- the population of T lymphocytes does not comprise or consist essentially of cells selected from the group of NKT cells, CD4+ T lymphocytes and T regulatory lymphocytes.
- the population of lymphocytes comprises memory T cells. In one embodiment, the population of lymphocytes comprises effector T cells and memory T cells.
- the T lymphocytes used in the adoptive T cell cancer therapy according to the present disclosure are TILs.
- the population of T lymphocytes comprises or consists essentially of TILs.
- lymphocytes to expand the number of lymphocytes, including tumor- infiltrating lymphocytes, such as T cells
- T cells can be accomplished by any of a number of methods as are known in the art.
- T cells can be rapidly expanded using non-specific T-cell receptor stimulation in the presence of feeder lymphocytes and interleukin-2 (IL-2), IL-7, IL-15 and IL-21 , with IL-2 being preferred.
- IL-2 interleukin-2
- IL-7 interleukin-7
- IL-15 interleukin-21
- T cells for use according to the ACT methods described herein can also be obtained from blood, lymphoid tissue (e.g. spleen) or from a tumor (e.g. tumor infiltrating lymphocytes).
- T cells for use according to the ACT methods described herein are produced from PBMCs that have a histocompatible phenotype to the subject with cancer to be treated. These PBMCs are thus heterologous to the subject with cancer to be treated. In related embodiments, the PBMCs are autologous to the subject with cancer to be treated.
- the T cells are genetically engineered to express T cell receptors (TCRs) that recognize human leukocyte antigen (HLA)/peptide complexes expressed by cancer cells or chimeric antigen receptors (CARs) of the individual to be treated.
- TCRs T cell receptors
- HLA human leukocyte antigen
- CARs chimeric antigen receptors
- the T lymphocytes have been cultured for between about 14 to about 40 days prior to administration to the individual. In one embodiment, the T lymphocytes have been cultured for about 19 to about 35 days prior to administration to the individual. In other embodiments of the disclosure, the administered lymphocytes have been cultured for less than 14 days and in yet other embodiments, the lymphocytes have been cultured for longer than 40 days prior to administration to the individual.
- the lymphocytes can be administered by any suitable route known in the art.
- the lymphocytes are administered as an intra-arterial or intravenous infusion, which may last about 30 to about 60 minutes.
- routes of administration include intraperitoneal, intrathecal and intralymphatic.
- lymphocytes can be administered.
- about 1 x 10 4 lymphocytes to about 1 x 10 10 lymphocytes are provided.
- x 10 5 lymphocytes to about 1 x 10 9 lymphocytes such as about 1 x 10 5 lymphocytes to about 1 x 10 8 lymphocytes, such as about 1 x 10 5 lymphocytes to about 1 x 10 7 lymphocytes, for example about 1 x 10 5 lymphocytes to about 1 x 10 6 lymphocytes, such as about 1 x 10 5 lymphocytes to about 9 x 10 5 lymphocytes, for example about 1 x 10 5 lymphocytes to about 8 x 10 5 lymphocytes, such as about 1 x 10 5 lymphocytes to about 7 x 10 5 lymphocytes, for example about 1 x 10 5 lymphocytes to about 6 x 10 5 lymphocytes, such as about 1 x 10 5 lymphocytes to about 5 x 10 5 lymphocytes, for example about 1 x 10 5 lymphocytes to about 4 x 10 5 lymphocytes, such as about 1 x 10 5 lymphocytes to about 3 x 10 5 lymphocytes, for example about 2 x 10 5 lymphocytes
- the T lymphocytes may be administered one or more times to the individual.
- Inhibition of Prosl was shown to increase the expression of the genes selected from the group consisting of LTA, TNFSRF9, IL-2, and IFN-g. Inhibition of Prosl was shown to decrease the expression of the genes selected from the group consisting of IL4R, DUSP4, CD99, ITGAL and CCL5.
- the cancer to be treated by the methods of the present disclosure can be any cancer that is likely to benefit from ACT, including any of acute lymphocytic leukaemia, acute myeloid leukaemia, alveolar rhabdomyosarcoma, bone cancer, brain cancer, breast cancer, cancer of the anus, anal canal, or anorectum, cancer of the eye, cancer of the intrahepatic bile duct, cancer of the joints, cancer of the neck, gallbladder, or pleura, cancer of the nose, nasal cavity, or middle ear, cancer of the vulva, chronic lymphocytic leukaemia, chronic myeloid cancer, cervical cancer, glioma, Hodgkin lymphoma, hypopharynx cancer, kidney cancer, larynx cancer, liver cancer, lung cancer, malignant mesothelioma, melanoma, multiple myeloma, nasopharynx cancer, non-Hodgkin lymphoma, ovarian cancer,
- the cancer can be a recurrent cancer.
- the cancer is a solid cancer.
- the cancer is selected from melanoma, ovarian, breast and colorectal cancer.
- the cancer is a cancer of the hematopoietic or lymphoid system.
- the cancer is melanoma, such as cutaneous metastatic melanoma.
- the individual to be treated according to the methods described herein may be any subject likely to benefit from ACT.
- the individual is usually a mammal, preferably a human.
- mammal refers to any mammal, including, but not limited to, mammals of the order Rodentia, such as mice and hamsters, and mammals of the order Lagomorpha, such as rabbits. It is preferred that the mammals are from the order Carnivora, including Felines (cats) and Canines (dogs). It is more preferred that the mammals are from the order Artiodactyla, including Bovines (cows) and Swines (pigs) or of the order
- Perssodactyla including Equines (horses). It is most preferred that the mammals are of the order Primates, Ceboids, or Simoids (monkeys) or of the order Anthropoids
- CD8 T cells used in ACT are not stimulated with a MerTK ligand but rather express a constitutive active MerTK, thus allowing for constitutive MerTK signalling without ligand stimulation.
- CD8 T cells can e.g. be isolated from tumor tissue, i.e. TILs, or CD8 T cells from blood samples can be rendered tumor specific by genetic modification e.g. by forced introduction, e.g., by viral transduction with a vector expressing a receptor that recognize cancer cells, e.g., a T cell receptor (TCR), or a chimeric antigen receptor (CAR).
- TILs tumor tissue
- CD8 T cells from blood samples can be rendered tumor specific by genetic modification e.g. by forced introduction, e.g., by viral transduction with a vector expressing a receptor that recognize cancer cells, e.g., a T cell receptor (TCR), or a chimeric antigen receptor (CAR).
- TCR T cell receptor
- CAR chimeric antigen receptor
- Such tumor specific T cells can be further manipulated to express a constitutively active form of MerTK, e.g. as described previously by Kasikara et al., e.g, by viral transduction, in turn leading to T cells having improved cytokine production and proliferation and ultimately improved effect in ACT.
- MerTK constitutively active form of MerTK
- the present disclosure provides a CD8+ T lymphocyte genetically modified to express a constitutive active MerTK.
- the CD8+ T lymphocyte genetically modified to express a constitutive active MerTK may in turn be used in a method of ACT cancer therapy.
- the present disclosure is further described by the following examples that should not be construed as limiting the scope of the disclosure.
- Biopsies from patients with stage III or IV melanoma was collected from 2006- 2013, and used for expansion of tumor infiltrating lymphocytes (TIL).
- Biopsy material was cut into small fragments (1-2 mm2) and kept overnight (ON) in a humidified 37°C CO 2 incubator. The following day, tumor fragments and cells were resuspended, washed twice in 1xPBS (Lonza) by centrifugation for 5 minutes at 1500 RPM and cryopreserved in fetal bovine serum (FBS, Gibco) + 10% DMSO (Sigma Aldrich). All biopsies originated from lymph nodes LN metastases removed under palliative surgery. Antibodies and reagents
- anti-CD3 clone UCHT1
- anti-CD8 RPA-T8
- anti-CD45RO UCHL-1 , all BD Biosciences
- anti-CD4 SK3
- anti-CCR7 G043H7, all Biolegend
- anti-PROS1 PS7, Santa Cruz Biotechnologies
- anti-MerTK anti-Tyro3
- anti-Axl 108724, all R&D Systems
- TIL tumor infiltrating lymphocytes
- Cell suspensions were thawn and placed in 24 well-culture plates (Nunc, Roskilde, Denmark) together with 2 ml of culture medium (90% RPMI 1640 (Invitrogen), 10% heat inactivated Human AB serum (Sigma-Albricht, USA), IL-2 6000 lU/ml (6000 lU/ml IL-2, Proleukin, Novartis), penicillin, streptomycin and fungi zone (Bristol-Myers Squibb, Lyngby, Denmark). Cells were split into 2-3 wells when cell concentration in 1 well exceeded 1.5 x 106 cells/ml.
- culture medium 90% RPMI 1640 (Invitrogen), 10% heat inactivated Human AB serum (Sigma-Albricht, USA), IL-2 6000 lU/ml (6000 lU/ml IL-2, Proleukin, Novartis), penicillin, streptomycin and fungi zone (Bristol-Myers Squibb, Lyngby, Denmark
- Expansions were set up in culture triplicates plus Prosl (50 nM PROS1 (Hematologic Technologies)), plus mAb Prosl (10 mg/ml, clone PS7, Santa Cruz Biotechnologies) , and control expansions. Outgrowth of T cells measured by counting of live CD3 positive T cells, and fold expansion was calculated.
- ELISA was used to study levels of IFN-g and TNF-a (ELISA Ready-Set-Go kits,
- CD3/CD28 bead stimulated T cell cultures upon addition of prosl or aProsl mAb.
- CD3/CD28 bead stimulated T cell cultures were studied upon siRNA gene knock down. Culture supernatants were tested at different dilutions following the manufacturer’s protocol.
- Human CD8+ T cells were isolated from human PBMCs by negative selection using MagniSortTM Human CD8 T cell Enrichment Kit, according to the manufacturer’s instructions (Thermo Fisher Scientific). Purified total CD8 T cells, or for some experiments total PBMCs, were cultured in the presence (1 :1 ratio) or absence of anti- human CD3/CD28 coated Dynabeads (Thermo Fisher Scientific) in X-VIVO 15 medium (Lonza), supplemented with 5% human serum and 50 U/ml hlL-2 for 1 to 7 days. To evaluate PROS1 and TAM receptor expression, cells were harvested daily (for surface expression) or after 3 days (for RT-qPCR).
- cells were cultured in serum free medium in the presence or absence of 50 nM PROS1 (Hematologic Technologies) and cells were harvested for analysis after 3 days of activation.
- PROS1 blocking experiments cells were cultured in medium with 5% human serum for 3-5 days prior to analysis, in the presence or absence of anti-PROS1 (clone PS7, Santa Cruz
- Membranes were incubated with primary antibodies (rabbit anti-human MERTK (D21 F11 , Cell Signalling), at 4°C overnight in TBS-T with 5% BSA and reprobed with mouse anti-human actin (C4, SCBT)). After several washing steps and incubation with HRP-linked secondary antibodies (Cell Signalling), proteins were detected using SuperSignal West ECL Kit and BioRad Analyzer. Quantification of signal was done using Fiji ImageJ (v.1.49).
- RNA isolation was done using the NucleoSpin® RNA kit (Cat# 740955.50, MACHEREY-NAGEL, Düren, Germany) kit according to manufacturer’s instructions.
- RNA was reverse-transcribed to cDNA using Superscript® VI LOTM cDNA Synthesis Kit (Invitrogen, Thermo Fisher Scientific, Cat# 11754-050).
- qPCR was performed in Agilent AriaMX System using the Brilliant III Ultra- Fast QPCR Master Mix (Agilent). Amplified products were checked by dissociation curves and expression was normalized to housekeeping genes.
- a set of three Stealth siRNA duplexes for targeted silencing of human MERTK were obtained from Invitrogen.
- three siRNAs with scrambled sequences possessing similar GC content were used.
- three-day stimulated CD8+ T cells were transfected with MERTK or Mock siRNA with the ECM830 square wave electroporation system (BTX) using electroporation parameters as previously described. Knockdown on protein level was confirmed for every individual experiment.
- BTX square wave electroporation system
- TILs The tumor-specific killing ability of TILs was assessed with a novel impedance-based cytotoxicity assay. Briefly, antigen-specific TILs were thawed and rested in IL-2 free media (RPMI 1640 supplemented with 10% human serum, penicillin and streptomycin) for 72 hours. Autologous tumor cells were seeded on E-plate 96 plates (ACEA Biosciences Inc) which were loaded onto RTCA SP real-time cell analyzer (ACEA Biosciences Inc). After 24 hours, TILs were added with or without 50 nM PROS1.
- IL-2 free media RPMI 1640 supplemented with 10% human serum, penicillin and streptomycin
- RNA and protein samples were split and processed separately. Transcriptomic analysis was performed using the nCounter Vantage 3D RNA:Protein Immune Cell Signaling Panel. Samples were subsequently processed in the fully automated nCounter Prepstation (NanoString Technologies) and analyzed in the nCounter Digital Analyzer (NanoString Technologies).
- nSolver4 software (NanoString Technologies) was used for data normalization and differential gene expression analyses.
- the significance of differential gene expression between paired groups was estimated using a mixed module significance testing with the algorithm included in the nCounter Advanced Analysis. In this module, a negative binomical mixture model for low expression probes or a simplified negative binomial model for high expression probes was used. Differential expression is indicated as the log2 fold change in gene or protein expression and the obtained p-values were adjusted for multiple testing by the Benjamini and Hochberg method (BH. p-value) to control the false discovery rate. Differentially expressed genes and proteins were depicted as volcano plot using R/RStudio v1.0.44.
- the bioenergetics from CD8+ T cells were measured in the presence or absence of co- stimulatory MERTK signalling in real-time using an XF-96 Extracellular Flux Analyzer.
- aCD3/CD28 stimulated CD8+ T cells were grown in the presence or absence of 50 nM PROS1 (serum free medium) or aPROS1 (10 mg/ml, serum-containing medium) for three days prior to use.
- Oxygen consumption rates (OCR) and extracellular acidification rates (ECAR) were measured where after wells were treated with 1 mM oligomycin and 10 mM 2-deoxy-D- glucose to measure ATP turnover and glycolytic capacity from the changes in OCR and ECAR respectively, or with 0.4 pM carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone (FCCP) to determine reserve respiratory capacity from change in OCR. All wells received a final treatment with 2mM Antimycin A.
- Expansion conditions included culture medium in the presence or absence of 50 nM PROS1 or 10 mg/ml aPROS1. Outgrowth of‘young’ TILs was measured by manual, unblinded counting of live cells and fold expansion was calculated.
- TILs designated for in vitro killing assays were isolated and expanded in vitro from metastatic melanoma lesions with a two-step process as described previously (52). Expanded TILs with high specificity for the HLA-A2 restricted MART-1 /MelanA peptide analogue ELAGIGILTV (>90% specific with peptide-MHC multimer staining) were obtained through electronic sorting of relevant CD8+‘young’ TILs, using peptide-MHC multimers. TILs were subsequently subjected to the rapid expansion protocol, as previously described.
- cells were cultured in medium with 5% human serum with aPROS1 (10 mg/ml) or unconjugated Annexin V (5 mg/ml), respectively.
- High TAM receptor-expressing MDA-MB-231 cell line was cultured in serum-free X-VIVO medium for 1 week prior to co-culture. Subsequently, MDA-MB-231 cells were plated in a flat-bottom 96-well plate and left to adhere for approximately 4 hours. Sorted allogenic non-reactive CD8+ T cells and aCD3/CD28 beads were added in a 1 :10 tumor cell:T cell ratio. A PROS1 titration was added in the range of 0-100 nM PROS1. After 4 days of co-culture, supernatants were harvested and analyzed by ELISA. Example 1. MerTK receptor and ligand PROS1 are expressed by TCR-activated human CD8+ T cells.
- T cells was evaluated by RT-qPCR.
- MerTK protein expression was analysed on day 3 of activation of PBMCs or CD8+ T cells, as analysed by western blot.
- the results are shown in fig. 1.
- Example 2 Positive regulates CD8+ T cell proliferation.
- Human CD8+ T cells were cultured in serum-free medium, stained with a proliferation dye (CTV, Cell Trace Violet), and activated for 3 days with aCD3/CD28 in the presence or absence of 50 nM PROS1. Proliferation was measured by flow cytometry and IFN-g as well as TNF-a production was measured in culture supernatants.
- CTV Cell Trace Violet
- Example 3 PROS1 impacts on human melanoma TIL expansion.
- TAM signalling in CD8 T cells represent an important co- stimulatory immune checkpoint. Since both cancer cells and activated T cells express ligands for Prosl , we hypothesize that the TAM axis plays a role in suppressing T cell functionality upon interaction with cancer cells: We propose that cancer cells through upregulated expression of TAMs compete for stimulatory Prosl secreted by T cells, by which cancer cells acquire a dual advantage; prevent the stimulatory TAM signalling in the T cell, and at the same time augment intrinsic oncogenic TAM signalling.
- this strategy for T cell suppression would potentially inflict on all T cells interacting with cancer cells in the microenvironment, not just T cells expressing individual inhibitory immune check point molecules, e.g., PD-1.
- TILs from 4 metastatic melanoma patients were isolated, cultured and expanded according to the clinical Rapid Expansion Protocol in the presence or absence of 50 nM PROS1 or aPROS1 mAb.
- Total live cells were counted and fold expansion was calculated on day 16 and 23 of culture, relative to day 0.
- Tumor biopsy material was digested and homogenized and equal“tumor soups” were put in culture in normal media, media plus Prosl , and media with blocking of Prosl (aPros).
- Outgrowth of T cells was given as fold expansion, showing a clear trend towards limited outgrowth when prosl was blocked, and possibly a positive impact when Prosl was added.
- MERTK expression was analysed on three-day activated CD8+ T cells which were co-stained with subset markers CCR7 and CD45R0. MERTK expression was significantly higher expressed on TCM CD8+ T cells. The results are shown in fig. 5.
- Example 5 PROS1 co-stimulation on CD8+ T cells acts via MERTK
- CD3/CD28 human PBMCs were activated with a pool of 23 peptides derived from cytomegalovirus, Epstein-Barr virus and influenza.
- CD137 recently TCR- activated, naturally occurring, CD8+ T cells can be accurately identified .
- CD3/CD28-activation The results are shown in fig. 6. Additionally, we found that resting or activated CD8+ T cells expressed only low levels of TYRO3 and do not express AXL (data not shown).
- Example 6 PROS1 induces CD8+ T cell cytokine production.
- Human CD8+ T cells were cultured in serum-free medium and activated for 3 days with aCD3/CD28 in the presence or absence of 50 nM PROS1. Chemokine CXCL10 and memory IL-7 production was measured in culture supernatants.
- Example 7 PROS1 co-stimulation on CD8+ T cells acts via MERTK.
- MERTK signaling in activated CD8+ T cells was inhibited.
- siRNA-mediated knockdown of MERTK As our earlier results have shown that resting T cells do not express MERTK, CD8+ T cells were activated for three days prior to siRNA electroporation. We confirmed that siRNA knockdown resulted in a 70% reduction in MERTK protein levels compared to control. When re-activated, MERTK- knockdown cells produced less IFN-g. Moreover, IL-7, but not IL-15, secretion was significantly decreased.
- MERTK inhibition significantly decreased aCD3/CD28-mediated CD8+ T cell proliferation, while no decrease in cell viability was seen.
- MERTK inhibition could reverse the positive effects of PROS1 on IFN-g secretion. The results are shown in fig. 8.
- the metabolism of activated CD8+ T cells in the presence or absence of PROS1- MERTK signalling was investigated. Bioenergetic phenotypes are shown to be strongly predictive for CD8+ T cell differentiation into the various memory subsets. Strikingly, the basal respiration rate of PROS1 -blocked cells was significantly decreased to 35% of control-stimulated cells. Accordingly, the ATP turnover of PROS1 -blocked cells was reduced to 31 %. Finally, the reserve respiratory capacity (SRC) of PROS1 -blocked cells was significantly decreased. This contrasts with activated CD8+ T cells supplemented with PROS1 , where no significant changes were found.
- SRC reserve respiratory capacity
- the gene encoding the transcription factor IRF4 was downregulated in PROS1-blocked cells versus control (Fig. 1 1 ). IRF4 has previously been correlated with metabolic programming of CD8+ T cells where it induces a metabolic shift, essential for antigen- specific responses and effector differentiation and function
- Example 12 PROS1 -MERTK signaling affects melanoma TIL outgrowth and functionality
- PROS1 -supplementation increased TIL-mediated killing in stepwise increments dependent on PROS1 levels (Fig. 12D). Cytokine secretion by T cells was inhibited at low levels of PROS1 as shown in the co-culture experiments, supposedly due to ligand competition (Fig. 12B).
- PROS1 surface staining was party reversible by blockage of PtdSer ( Figure 13).
- activated CD8+ T cells significantly increased TAM receptor MERTK surface expression from day two onwards, only on PROS1 -positive cells.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La présente invention concerne une méthode pour améliorer l'efficacité clinique d'une thérapie adoptive par lymphocytes T avec un ligand de MerTK. L'invention concerne en outre un ligand de MerTK destiné à être utilisé dans le traitement d'un cancer chez un individu, ledit procédé comprenant la thérapie adoptive par lymphocytes T.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18168195 | 2018-04-19 | ||
EP18168195.8 | 2018-04-19 | ||
EP18210051 | 2018-12-04 | ||
EP18210051.1 | 2018-12-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019201970A1 true WO2019201970A1 (fr) | 2019-10-24 |
Family
ID=66165983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2019/059877 WO2019201970A1 (fr) | 2018-04-19 | 2019-04-17 | Ligand de mertk pour la thérapie adoptive anicancéreuse par lymphocytes t |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2019201970A1 (fr) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007032634A1 (fr) * | 2005-09-12 | 2007-03-22 | Industry Foundation Of Chonnam National University | Methode de production de cellule tueuse naturelle mature |
WO2016106221A1 (fr) | 2014-12-22 | 2016-06-30 | The Rockefeller University | Anticorps agonistes anti-mertk et leurs utilisations |
-
2019
- 2019-04-17 WO PCT/EP2019/059877 patent/WO2019201970A1/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007032634A1 (fr) * | 2005-09-12 | 2007-03-22 | Industry Foundation Of Chonnam National University | Methode de production de cellule tueuse naturelle mature |
WO2016106221A1 (fr) | 2014-12-22 | 2016-06-30 | The Rockefeller University | Anticorps agonistes anti-mertk et leurs utilisations |
Non-Patent Citations (12)
Title |
---|
ANDERSEN, R.; M. DONIA; E. ELLEBAEK; T. HOLZ BORCH; P. KONGSTED; T. Z. IVERSEN; L. ROSENKRANTZ HOLMICH; H. WESTERGREN HENDEL; O. M: "Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL-2 regimen", CLINICAL CANCER RESEARCH, vol. 22, 2016, pages 3734 - 3745 |
CABEZON ET AL.: "MERTK as negative regulator of human T cell activation", J. LEUKOCYTE BIOLOGY, vol. 97, no. 4, 2015, pages 751 - 760 |
CABEZÓN RAQUEL ET AL: "MERTK as negative regulator of human T cell activation.", JOURNAL OF LEUKOCYTE BIOLOGY APR 2015, vol. 97, no. 4, April 2015 (2015-04-01), pages 751 - 760, XP002792069, ISSN: 1938-3673 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; February 2012 (2012-02-01), MIGDALL-WILSON JUSTINE ET AL: "Prolonged Exposure to a Mer Ligand in Leukemia: Gas6 Favors Expression of a Partial Mer Glycoform and Reveals a Novel Role for Mer in the Nucleus", XP002792070, Database accession no. PREV201200408432 * |
HÖLSKEN OLIVER ET AL: "Exploiting natural killer cells for therapy of melanoma.", JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT = JOURNAL OF THE GERMAN SOCIETY OF DERMATOLOGY : JDDG JAN 2015, vol. 13, no. 1, January 2015 (2015-01-01), pages 23 - 29, XP002792073, ISSN: 1610-0387 * |
JUNE, C. H.: "Serial Killers and Mass Murderers: Engineered T Cells Are up to the Task", CANCER IMMUNOL. RES., vol. 3, 2015, pages 470 - 472 |
KASIKARA, C.; S. KUMAR; S. KIMANI; W. I. TSOU; K. GENG; V. DAVRA; G. SRIRAM; C. DEVOE; K. Q. NGUYEN; A. ANTES: "Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy", CLIN. CANCER RES., vol. 17, 2011, pages 4550 - 4557, XP055144006, DOI: doi:10.1158/1078-0432.CCR-11-0116 |
LIHUA E. BUDDE ET AL: "Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma", PLOS ONE, vol. 8, no. 12, 17 December 2013 (2013-12-17), pages e82742, XP055213511, DOI: 10.1371/journal.pone.0082742 * |
MELIEF SARA M ET AL: "IDO and galectin-3 hamper the ex vivo generation of clinical grade tumor-specific T cells for adoptive cell therapy in metastatic melanoma", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN/HEIDELBERG, vol. 66, no. 7, 11 April 2017 (2017-04-11), pages 913 - 926, XP036266764, ISSN: 0340-7004, [retrieved on 20170411], DOI: 10.1007/S00262-017-1995-X * |
PLOS ONE, vol. 7, no. 2, February 2012 (2012-02-01), DOI: 10.1371/JOURNAL.PONE.0031635 * |
RUVOLO PETER P ET AL: "Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms.", HAEMATOLOGICA 12 2017, vol. 102, no. 12, December 2017 (2017-12-01), pages 2048 - 2057, XP002792071, ISSN: 1592-8721 * |
TRAN, E.; S. TURCOTTE; A. GROS; P. F. ROBBINS; Y. C. LU; M. E. DUDLEY; J. R. WUNDERLICH; R. P. SOMERVILLE; K. HOGAN; C. S. HINRICH: "Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer", SCIENCE, vol. 344, 2014, pages 641 - 645, XP055161464, DOI: doi:10.1126/science.1251102 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7181917B2 (ja) | 濃縮された腫瘍反応性t細胞集団を腫瘍から作製する方法 | |
JP7252383B2 (ja) | 末梢血から腫瘍反応性t細胞の濃縮された集団を作製する方法 | |
JP7451468B2 (ja) | 非造血組織常在性γδ T細胞の増幅および該細胞の使用 | |
JP7315435B2 (ja) | 抗ヒトパピローマウイルス抗原t細胞の調製方法 | |
US10653756B2 (en) | Identification of CD8+ T cells that are CD161hi and/or IL18R(α)hi and have rapid drug efflux capacity | |
ES2643387T3 (es) | Estirpe celular de linfocitos que comprende células gama-delta, composición y método de producción de la misma | |
Peeters et al. | MERTK acts as a costimulatory receptor on human CD8+ T cells | |
WO2017048614A1 (fr) | Procédés d'isolement de récepteurs de lymphocytes t réactifs à une tumeur à partir de tumeur ou de sang périphérique | |
US20220378826A1 (en) | Tumour infiltrating lymphocyte therapy and uses thereof | |
EP3052085A1 (fr) | Activation de cellules nkt médiée par des cellules présentatrices de l'antigène artificielles à base de nanoparticules | |
WO2020109616A1 (fr) | Modification de lymphocytes t | |
JP2022543026A (ja) | Nk細胞を評価するためのシステム及び方法 | |
WO2011013129A1 (fr) | Sélection de lymphocytes pour le traitement du cancer | |
WO2019201970A1 (fr) | Ligand de mertk pour la thérapie adoptive anicancéreuse par lymphocytes t | |
WO2017176932A1 (fr) | Méthodes de traitement du cancer et de maladies infectieuses à l'aide de thérapies à base de cellules | |
JP7014820B2 (ja) | 胚性間葉系始原細胞の製造方法及び使用方法 | |
Pan et al. | Natural Killer Cells at the Forefront of Cancer Immunotherapy with Immune Potency, Genetic Engineering, and Nanotechnology | |
RU2808817C2 (ru) | Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток | |
Liu et al. | IP-10 enhances the amplification capacity and antitumor activity of CAR-T cells in vitro and could influence positive outcomes in MM patients treated with CAR-T cell therapy | |
Jordan et al. | AXL inhibition suppresses early allograft monocyte-to-macrophage differentiation and prolongs allograft survival | |
Heimann | Elongated T cell expansion by utilizing IL7 and IL15 leads to increased T cell yield while preserving Tcm/Tscm characteristics feasible for adoptive T cell therapy | |
Schötterl | Functional and therapeutic effects of viscumins in the treatment of experimental glioblastoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19717322 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19717322 Country of ref document: EP Kind code of ref document: A1 |